Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 30 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 25 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
20(74.1%)
Phase 2
6(22.2%)
Early Phase 1
1(3.7%)
27Total
Phase 1(20)
Phase 2(6)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT07472270Phase 1Not Yet Recruiting

Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment

Role: lead

NCT07432334Phase 1Not Yet Recruiting

CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus

Role: lead

NCT05307536Phase 2Completed

Autologous BMMNCs Combined With Educational Intervention for ASD

Role: lead

NCT05331872Phase 1Completed

Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis

Role: lead

NCT06726538Phase 1Completed

Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50

Role: lead

NCT06629324Phase 2Recruiting

Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia

Role: lead

NCT06027957Phase 1Completed

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Role: lead

NCT04919135Phase 1Completed

Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty

Role: lead

NCT05308836Phase 1Completed

Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment

Role: lead

NCT05292625Phase 1Completed

Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke

Role: lead

NCT05293873Phase 1Completed

Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae

Role: lead

NCT04080921Phase 1Completed

Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis

Role: lead

NCT04516954Early Phase 1Completed

Convalescent Plasma for COVID-19 Patients

Role: lead

NCT04522869Phase 1Completed

Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia

Role: lead

NCT04521036Phase 1Completed

Convalescent Plasma for COVID-19 Patients (CPCP)

Role: lead

NCT05345418Phase 1Recruiting

Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency

Role: lead

NCT05329662Phase 2Recruiting

Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female

Role: lead

NCT04062136Phase 1Completed

Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia

Role: lead

NCT03468699Phase 2Completed

Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia

Role: lead

NCT03346967Phase 1Completed

Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency

Role: lead